Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:12 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection
NCT04377659 · Memorial Sloan Kettering Cancer Center · PHASE2 · terminated · last registry update 2025-05-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Based on two large, multicenter, randomized trials showed no benefit to tocilizumab in this setting and study has been closed.” | – | Registry record, Memorial Sloan Kettering Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL6R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-05-26Results posted on the registry: Memorial Sloan Kettering Cancer Center, Cyclosporine + Mycophenolate Mofetil (NCT03434730)
- 2026-05-12Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Cobimetinib (NCT03337698)
- 2026-05-12Also stopped (terminated): Hoffmann-La Roche, Atezolizumab + Cobimetinib (NCT03337698)
- 2026-05-06Phase 3 first posted: Merck Sharp & Dohme LLC, MK-1045 + Blinatumomab (NCT07570173)
- 2026-04-03Phase 3 first posted: Capital Medical University, Tocilizumab + Placebo (NCT07509645)
- 2026-03-06Results posted on the registry: Hoffmann-La Roche, Mosunetuzumab + Polatuzumab vedotin (NCT05171647)
- 2026-02-10Also stopped (terminated): Queen's Medical Center, Tocilizumab + Placebo (NCT04412772)
- 2026-01-22Results posted on the registry: Takeda, TAK-500 + Pembrolizumab (NCT05070247)
- 2026-01-22Also stopped (terminated): Takeda, TAK-500 + Pembrolizumab (NCT05070247)
- 2026-01-13Phase 3 first posted: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, BMS-986353 + Fludarabine (NCT07335562)
- 2025-12-16Phase 3 first posted: Sanofi, Sarilumab + Sarilumab (NCT07286214)
- 2025-12-15Phase 3 first posted: Yale University, Anakinra + Tocilizumab (NCT07281027)
- 2025-12-04Phase 3 first posted: Capital Medical University, Tocilizumab + Placebo (NCT07263776)
- 2025-11-21Results posted on the registry: Hoffmann-La Roche, Nab-Paclitaxel + Gemcitabine (NCT03193190)
- 2025-11-13Also stopped (suspended): Massachusetts General Hospital, Tocilizumab + Placebo (NCT03787290)
- 2025-10-06Results posted on the registry: Biogen, BIIB800 + Actemra (NCT06262477)
- 2025-09-29Also stopped (withdrawn): BayCare Health System, Sarilumab 200 MG/1.14 ML Subcutaneous Solution + Placebo (NCT07196306)
- 2025-06-17Results posted on the registry: Cambridge University Hospitals NHS Foundation Trust, Rituximab + Infliximab (NCT05168475)
- 2025-06-17Also stopped (terminated): Cambridge University Hospitals NHS Foundation Trust, Rituximab + Infliximab (NCT05168475)
- 2025-06-12Results posted on the registry: Assistance Publique - Hôpitaux de Paris, Sarilumab (NCT04324073)
- 2025-06-12Results posted on the registry: Assistance Publique - Hôpitaux de Paris, Tocilizumab (NCT04331808)
- 2025-06-05Results posted on the registry: University of Chicago, Tocilizumab + Tocilizumab (NCT04479358)
- 2025-03-04Also stopped (withdrawn): University of Florida, Satralizumab (NCT05727657)
- 2025-02-28Results posted on the registry: Hoffmann-La Roche, Satralizumab (NCT04963270)
- 2025-02-28Also stopped (terminated): Hoffmann-La Roche, Satralizumab (NCT04963270)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision